These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 20158106)
41. The Role of PPAR-γ in Allergic Disease. Stark JM; Coquet JM; Tibbitt CA Curr Allergy Asthma Rep; 2021 Oct; 21(11):45. PubMed ID: 34697644 [TBL] [Abstract][Full Text] [Related]
42. Significance of anti-inflammatory effects of PPARgamma agonists? Rogler G Gut; 2006 Aug; 55(8):1067-9. PubMed ID: 16849341 [TBL] [Abstract][Full Text] [Related]
43. Antiallergic benefit of marine algae in medicinal foods. Kim SK; Vo TS; Ngo DH Adv Food Nutr Res; 2011; 64():267-75. PubMed ID: 22054954 [TBL] [Abstract][Full Text] [Related]
44. Amorfrutins Are Natural PPARγ Agonists with Potent Anti-inflammatory Properties. Fuhr L; Rousseau M; Plauth A; Schroeder FC; Sauer S J Nat Prod; 2015 May; 78(5):1160-4. PubMed ID: 25938459 [TBL] [Abstract][Full Text] [Related]
45. [Application of basic research to development of diagnostics and therapeutic agents against inflammatory diseases]. Izuhara K; Ohta S; Arima K; Suzuki S; Inamitsu M; Yamamoto K Rinsho Byori; 2013 Oct; 61(10):900-8. PubMed ID: 24371994 [TBL] [Abstract][Full Text] [Related]
46. Design and application of locally delivered agonists of the adenosine A(2A) receptor. Mantell S; Jones R; Trevethick M Expert Rev Clin Pharmacol; 2010 Jan; 3(1):55-72. PubMed ID: 22111533 [TBL] [Abstract][Full Text] [Related]
47. PPAR gamma, bioactive lipids, and cancer progression. Robbins GT; Nie D Front Biosci (Landmark Ed); 2012 Jan; 17(5):1816-34. PubMed ID: 22201838 [TBL] [Abstract][Full Text] [Related]
48. Targeted therapy for allergic diseases: at the intersection of cutting-edge science and clinical practice. Boguniewicz M; Leung DY J Allergy Clin Immunol; 2015 Feb; 135(2):354-6. PubMed ID: 25662304 [No Abstract] [Full Text] [Related]
49. International perspectives on controversial practices in allergic diseases: the South American experience. Malka S; Capriles-Hullet A; Sánchez-Borges M; Pérez-Lozano A Clin Rev Allergy Immunol; 1996; 14(3):271-87. PubMed ID: 8932957 [TBL] [Abstract][Full Text] [Related]
50. New Drugs in Allergy and Asthma. Proceedings of an international conference. Davos, July 8-10, 1992. Agents Actions Suppl; 1993; 43():1-307. PubMed ID: 8103621 [No Abstract] [Full Text] [Related]
51. Teaching of allergic diseases in Australia. Garrett MH Med J Aust; 1969 Mar; 1(13):707. PubMed ID: 5769464 [No Abstract] [Full Text] [Related]
52. Private payer-negotiated prices for FDA-approved biologic treatments for allergic diseases. Wang AA; Rathi VK; Xiao R; Holbrook EH; Scangas GA; Workman AD; Gray ST Int Forum Allergy Rhinol; 2022 May; 12(5):798-801. PubMed ID: 34821065 [No Abstract] [Full Text] [Related]
53. [The use of adrenergic drugs in allergic diseases]. Tinoco N0uñez C; Garza Salinas S Alergia; 1967 Aug; 15(1):19-28. PubMed ID: 5595698 [No Abstract] [Full Text] [Related]
54. Pathophysiological Roles of PPARgamma in Gastrointestinal Epithelial Cells. Necela BM; Thompson EA PPAR Res; 2008; 2008():148687. PubMed ID: 18615192 [TBL] [Abstract][Full Text] [Related]
55. [The research progress of PPARγ in the Neurodegenerative disease]. Guo P; Wang XM; Wang DS Sheng Li Ke Xue Jin Zhan; 2015 Oct; 46(5):379-82. PubMed ID: 26904863 [No Abstract] [Full Text] [Related]